Conference Coverage: ASCO 2024 – Focus on Breast Cancer
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making coming out of the ASCO 2024 conference.
June 11, 2024
FACULTY CHAIR
Adam Brufsky, MD, PhD, FACP
UPMC Hillman Cancer Center, Pittsburgh, PA, USA
FACULTY MEMBERS
Mark Pegram, MD
Stanford University School of Medicine, Stanford, CA, USA
Joyce O’Shaughnessy, MD
Baylor University Medical Center, Dallas, TX, USA
William Sikov, MD, FACP, FNCBC
Women & Infants Hospital, Providence, RI, USA
Peter Schmid, FRCP, MD, PhD
Barts Cancer Institute, London, UK
Nadia Harbeck, MD, PhD
Ludwig Maximilian University of Munich, Germany
Javier Cortés, MD, PhD
International Breast Cancer Center, Barcelona, Spain
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- New and Emerging Treatments in HER2+ Metastatic BC (mBC)
- New and Emerging Approaches in HR+, HER2– Early BC
- New and Emerging Approaches in HR+, HER2– mBC
- Advances in Early Triple-Negative Breast Cancer (TNBC)
- Advances in Metastatic TNBC (mTNBC)
